|
About Us
 CritiTech,
Inc. conducts research and development into the production
and application of fine-particle compounds. The company has
expanded its operations to include applications in fine particle
API production, coatings, and internal product development.
Nanotax
Product Profile
CritiTech expects pharmaceutical manufacturers
to quickly recognize the superiority of CritiTech's proprietary
methods for precisely manufacturing fine particle pharmaceutical
compounds. The company's proprietary technology may allow
pharmaceutical companies to substantially increase the probabilities
of new compounds actually reaching the market place by enhancing
delivery of these compounds. Additionally, CritiTech's technology
can be used to extend the patent life for compounds currently
being marketed by developing formulations that have improved
bioavailability due to small particle size. This approach
has significant potential advantages over other delivery technologies
that require reformulation using "carriers" such
as liposomes or other compounds. Such approaches typically
require additional regulatory steps, while CritiTech's approach
can potentially produce improved bioavailability without the
use of such "carriers," thus avoiding the regulatory
burdens and expenses that such approaches impose in new product
development.
By many estimates between 30% and 40% of
all new chemical entities produced by pharmaceutical companies
have water solubility that is low enough to render the compound
unusable as a drug. CritiTech's patented technology can help
manufacturers overcome this problem.
A relatively small investment in the exploration
of the use of CritiTech's technologies can result in a dramatic
increase in the number of potential new drugs that a company
can investigate.
|
